E
Kazia Therapeutics Limited KZIA
$0.71 -$0.001-0.14%
Recommendation
Sell
Prev Close
$0.711
Volume
74,996
Avg Vol (90D)
1,357,826
Market Cap
$3.97M
Dividend & Yield
--
52-Week Range
$0.65 - $15.80
P/E (TTM)
--
EPS (TTM)
-$651.41
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Weak
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
3/31/2025 - GuruFocus
Kazia Therapeutics sells intellectual property and trademarks rights for Cantrixil
3/31/2025 - Seeking Alpha - Healthcare
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
3/31/2025 - The Fly
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
3/31/2025 - PR Newswire
Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Up 94.5% in March
3/29/2025 - Ticker Report
Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Decline in Short Interest
3/15/2025 - Ticker Report
Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Large Decline in Short Interest
2/28/2025 - Ticker Report
Kazia Therapeutics announces research grant awarded from MJFF
2/20/2025 - The Fly
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. ...
2/20/2025 - GuruFocus
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
2/20/2025 - PR Newswire
Maxim starts Kazia Therapeutics at Buy amid 'positive' GBM study data
2/6/2025 - The Fly
Kazia Therapeutics initiated with bullish view at Maxim, here's why
2/6/2025 - The Fly
Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
2/3/2025 - TipRanks Financial Blog
Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?
1/31/2025 - Insider Monkey
10 Best ASX Stocks to Buy According to Hedge Funds
1/30/2025 - Insider Monkey
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination ...
1/30/2025 - GuruFocus
Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
1/30/2025 - The Fly
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
1/30/2025 - PR Newswire
10 Best Australian Stocks to Buy Now
1/26/2025 - Insider Monkey
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
1/14/2025 - GuruFocus
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
1/14/2025 - PR Newswire
Kazia Therapeutics announces $2M registered direct offering
1/10/2025 - Seeking Alpha - Healthcare
Kazia Therapeutics announces $2M registered direct offering
1/10/2025 - SeekingAlpha.com: All News
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
1/10/2025 - TipRanks Financial Blog
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
1/10/2025 - The Fly
Income Statement
Total Revenue (TTM)
$1.63M
EBITDA (TTM)
-$17.47M
EBIT (TTM)
-$18.69M
Net Income (TTM)
-$17.58M
Balance Sheet
Total Assets (Q)
$14.40M
Total Debt (Q)
$423.00K
Total Liabilities (Q)
$21.08M
Book Value Per Share (Q)
-$200.79
Cash Flow
Cash from Operations (TTM)
-$6.28M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$3.92M
Net Change in Cash (TTM)
-$2.35M
Filings
Filing Date
Friday, November 15, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
2.16
7-Day Total Return
-25.26%
30-Day Total Return
-18.04%
60-Day Total Return
-57.99%
90-Day Total Return
-87.67%
Year to Date Total Return
-59.31%
1-Year Total Return
-80.48%
2-Year Total Return
-93.72%
3-Year Total Return
-99.13%
5-Year Total Return
-97.36%
52-week Low
Apr 04, 2025 - $0.65
52-week High
Jul 11, 2024 - $15.80
Valuation
Market Cap
$3.97M - Nano Cap
Enterprise Value
$3.29M
Price/Sales (TTM)
0.01
Price/Book (Q)
0.00
Dividends and Shares
Shares Outstanding
28.70K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.kaziatherapeutics.com
Phone Number
61 2 9472 4101
Address
Three International Towers
Level 24 - 300 Barangaroo Avenue
Sydney, NSW 2000
Country
Australia
Year Founded
1994
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule... more
NASDAQ 04/07/2025 3:46PM Eastern Quotes delayed
Weiss Ratings